Chronic Liver Diseases Therapeutics Market Growth Prospects 2026–2030 with Innovation Trends and Competitive Landscape
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Chronic Liver Diseases Therapeutics Market Projected To Become By 2030 Based On Its 2026 Valuation?
The chronic liver diseases therapeutics market has seen swift expansion in its size over recent years. It is projected to grow from $15.88 billion in 2025 to $17.56 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. The expansion observed in the historic period is attributable to several factors, including enhanced diagnosis of chronic liver conditions, the broader application of antiviral therapy, improved management of autoimmune liver diseases, expanded access to hospital-based liver care, and the development of specialty hepatology services.
The chronic liver diseases therapeutics market is anticipated to experience substantial expansion over the upcoming years, projected to reach $25.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. This projected growth during the forecast period is attributable to several factors, including heightened investments in therapies for NASH and fibrosis, a growing need for precise liver medicine, the proliferation of biologic and targeted treatment options, an increased emphasis on strategies for early intervention, and a surge in clinical trial activities for liver conditions. Key trends anticipated within this period encompass the escalating development of specialized liver therapies, a heightened focus on approaches tailored to specific diseases, the wider embrace of combination drug regimens, advancements in non-invasive disease monitoring techniques, and a stronger commitment to retarding the progression of liver diseases.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp
Which Market Drivers Are Supporting The Expansion Of The Chronic Liver Diseases Therapeutics Market?
The chronic liver disease therapeutics market is anticipated to expand as alcohol consumption rises. The consumption of alcohol involves drinking ethanol-containing beverages, spanning from moderate to heavy use, with potential health consequences. This increase in alcohol intake stems from greater global accessibility, rising incomes, and growing social acceptance. Therapies for chronic liver disease aid in managing liver damage resulting from high alcohol intake, thereby decelerating disease progression and enhancing liver function. For example, data from First Citizens Bank, a US financial institution, indicated a 1.2% rise in direct-to-consumer (DTC) wine case sales in 2023 versus 2022, as reported in June 2024. Furthermore, a December 2023 report by Kirin Holdings Company Limited, a Japan-based beverage firm, highlighted that approximately 192.1 million kiloliters of beer were consumed in 2022, representing a 2.9% increase from the prior year. Consequently, the rising consumption of alcohol is fueling the expansion of the chronic liver disease therapeutics market.
What Segment Groups Are Identified Within The Chronic Liver Diseases Therapeutics Market?
The chronic liver diseases therapeutics market covered in this report is segmented –
1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy
2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals
2) By Immunosuppressants Vaccines: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors
3) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin
4) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone
5) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies
6) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents
What Industry Trends Are Redefining The Chronic Liver Diseases Therapeutics Market?
Leading companies within the chronic liver disease therapeutics market are prioritizing the development of innovative solutions, such as engineered autologous macrophage cell therapy, aimed at boosting liver regeneration, slowing the progression of fibrosis, and delivering more focused, disease-modifying treatment options. Engineered autologous macrophage cell therapy describes a therapeutic method that utilizes a patient’s own macrophages, which are genetically altered or functionally improved outside the body before being reintroduced to decrease liver inflammation, foster tissue repair, and either slow down or reverse fibrosis in chronic liver diseases. For example, in June 2024, Resolution Therapeutics Ltd., a UK-based biotechnology company, obtained clearance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate its Phase I/II EMERALD study for its primary candidate, RTX001, which targets decompensated liver cirrhosis.
Which Companies Hold Significant Positions In The Chronic Liver Diseases Therapeutics Market?
Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.
Read the full chronic liver diseases therapeutics market report here:
How Is The Chronic Liver Diseases Therapeutics Market Distributed Across Key Geographic Regions?
North America was the largest region in the chronic liver diseases therapeutics market in 2025. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Chronic Liver Diseases Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21145&type=smp
Browse Through More Reports Similar to the Global Chronic Liver Diseases Therapeutics Market 2026, By The Business Research Company
Kidney Disease Global Market Report
https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report
Diabetic Kidney Disease Global Market Report
https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report
Late Stage Chronic Kidney Disease Drugs Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
